Provide an in-depth review of the global market for antibiotics resistance and antibiotics technologies
Offer an analysis of antibiotics resistance from an historical vantage point
Measure the current global market for antibiotics resistance and antibiotics technologies and provide market data for 2008, estimates for 2009, and compound annual growth rates (CAGRs) through 2014
Describe various products by classes, including penicillins and cephalsporins
Profile key players in the antibiotics market
Looks at government regulations adopted in various markets to combat antibiotics resistance.

Scope of Report

The scope of this report includes current antibiotic markets as well as the emerging antibiotic market, with an exclusive focus on antibiotic resistance. It technically encompasses antibacterials that include antibiotics, bacterial vaccines, and other emerging antibacterials that are not necessarily classified as antibiotics. Prevention of bacterial infections using bacterial vaccines is within the scope of the study. Antiviral and antifungal products are excluded from the market definition, and vaccines targeting viral diseases are outside the scope of this study. In short, this report contains: Overview of antibiotic market Classification of bacteria Classification of antibiotics Mechanisms of resistance by bacteria Resistance trends and geographic analysis Antibiotics targeted to counter the resistance mechanisms Emerging regulatory trends Technology trends in combating resistance Patent analysis Current antibiotic market and future growth trends Emerging new approaches and product candidates in antibiotic resistance Analysis of leading companies and their strategies Sales projections through 2014 for antibiotic resistance markets The base year of this study is 2009. Market figures are based on the revenues at the supplier levels, which are projected in 2009 constant dollars (i.e., inflation is not computed into the projection figures). The revenue figures are derived from the revenues of the key players in a particular year. Revenues of generic products are outside the scope of this study. Projections for the antibiotic resistance market are based on the assumption that the new and emerging products combat the antibiotic resistance issue in one way or another. Hence, forecasts are for the antibiotic resistance markets and are based mainly on the projections of the marketers.

Information Sources and Methodology

Both primary and secondary research methods were used in this market research study. The information and analysis presented in this report are based on an extensive survey of the antibacterial sector as well as a detailed examination of published literature and reports obtained from regulatory authorities, research institutions, trade associations, and national and international healthcare organizations. Key information from the literature was used to obtain expert opinion on commercial potential and market sizes from industry professionals. Data to prepare this study were derived from regulatory agencies, annual reports of companies, scientific associations, public healthcare authority websites, and industry related databases. In addition, discussion with researchers and sales personnel of drug companies, academic researchers, and government agency spokespersons have been conducted to gain insight into the emerging market trends.

Ananlyst's Credentials

Syamala Ariyanchira is a bench scientist who transferred to industry analysis. She combines her technical background with business sector issues and is involved in various activities, including technology assessment, strategic planning, competitor analysis, due diligence, and market analysis. Her clients include investment firms, government agencies, and chemical and pharmaceutical companies. She holds a PhD from Indian Institute of Science, Bangalore, India, and has authored three recent reports for BCC Research.

Chapter- 1: Introduction -- Complimentary
- Study Goal and Objectives
- Reasons for Doing The Study
- Intended Audience
- Scope of Report
- Information Sources and Methodology
- Ananlyst' S Credentials
- Related BCC Research Reports
- BCC Online Services
- Disclaimer
Chapter-2: Executive Summary
- Executive Summary
- Summary Table Current Antibiotics and New Products in The Global Market, through 2014 ($ Billions)
- Summary Figure Global Antibiotics Market by Product Classes, 2009 (%)
Chapter-3: Overview
- Microbiology of Infection
- Antibiotics and The Problem of Antibiotic Resistance
  - Table 1 Antibiotic Discovery and Resistance Development
- Bacteria: Classification, Identification, and Resistance Status of Various Classes
- Gram Positive Bacteria
- Bacillus Anthracis
- Clostridium
- C. Botulinum
- C. Difficle
- C. Perfringens
- C. Tetani
- Corynebacterium Diphtheriae
- Enterococci
- Erysipelothrix Rhusiopathiae
- Nocardia Asteroides
- Pneumococcus
- Staphylococcus
- Streptococcus
- Gram-Negative Bacteria
- Bordetella Pertussis
- Brucella
- Campylobacter
- Enterobacteriaceae
- Cedecea
- Citrobacter
- Enterobacter
- Escherichia Coli
- Klebsiella
- Salmonella
- Shigella
- Haemophilus
- Neisseria
- Vibrio Cholerae
- Mycobacteria
- Mycobacterium Tuberculosis
  - Table 2 U.S. Tuberculosis Cases and Deaths, 1998 - 2007
- Mycobacterium Leprae
- Mycobacteria Other than Tuberculosis (Mott)
- Spirochetes
- Borrelia Burgdorferi
- Treponema Pallidum
- Pathogen Disease Distribution
  - Table 3 Estimated Disease Incidence by Bacteria in Selected Countries, 2007
- Comparison of Nocosomial and Community Infections
- Hospital-Acquired (Ha)-Mrsa
- Community-Associated (Ca)-Mrsa
- Natural Defenses Present in The Combat of Infection
- Antiseptics
- Bacteria and Other Microorganisms of The Digestive Tract
- Classification of Antibiotics
- Bactericidal and Bacteriostatic
- Classification Based on Structure
- Penicillins
- Cephalosporins
- Fluoroquinolones
- Tetracyclines
- Macrolides
  - Table 4 Commonly Used Antibiotics by Class
- Classification Based on The Mode of Action of Antibiotics
- Cell Wall Inhibitors
- Cell Membrane Inhibitors
- Nucleic Acid Inhibitors
- Protein Synthesis Inhibitors
  - Table 5 Commonly Used Protein Synthesis Inhibitors
- Metabolic Inhibitors
- Fatty Acid Biosynthesis (Fab) Inhibitors
- Administration of Antibiotics
- Determining The Potency of Antibiotics
- Antibiotic Susceptibility Testing
- Drug Resistance: The Greatest Challenge Facing The Anti-Infective Drug Market
- The History of Antibiotic Resistance
- Current Crisis of Antibiotic Resistance
- The Microbiology of Antibiotic Resistance
- Mechanisms of Resistance Developed by Various Bacteria
- Enzymatic Deactivation or Modification of Antibiotic
- Esbl-Producing Organisms
- Alteration of The Target Site of The Antibiotic
- Alteration of The Metabolic Pathways
- Reducing The Potential for Drug Accumulation
- Biofilm Formation
  - Table 6 Human Infections Involving Biofilms
- Resistance in Gram-Positive Bacteria
- Methicillin-Resistant Staphylococcus Aureus (Mrsa)
- Vancomycin-Intermediate S. Aureus (Visa)
- Vancomycin-Resistant Enterococci (Vre)
- Multi-Drug-Resistant Clostridium Difficile
- Resistance in Gram-Negative Bacteria
- Multi-Drug-Resistant Acinetobacter Baumannii
- Enterobacteriacae- (Resistance by Esbl and Ampc-Beta Lactamase Production)
- Resistance in Pseudomonas Aeruginosa
- Tetracycline-Resistant, Penicillin-Resistant Neisseria Gonorrhoeae
- Antibiotic Resistance in Mycobacterium
  - Table 7 Mechanisms of Resistance by Bacteria Reported against Various Antibiotic Classes
- Cost of Antibiotic Resistance
  - Table 8 Economic Pressures Due to Antibiotic Resistance, Institutional and Societal
- Effects of Increasing Antibiotic Resistance
  - Table 9 Treatment Options for Resistant Bacteria
  - Table 9 (Continued)
- Antibiotic Stewardship Programs in Hospitals
  - Table 10 Essential Components of Antimicrobial Stewardship Programs
- Trends in Geographic Distribuition of Resistance
- Europe
- U.S.
  - Table 11 U.S. Antibiotic Resistance Trends of Some Critical Infections
  - Table 11 (Continued)
- Global Epidemiology Trends of Antibiotic Resistance: Rest of The World
  - Table 12 Rest of The World Epidemiology Trends of Antibiotic Resistance
Chapter-4: Regulatory Trends
- Politics of Bacterial Resistance
- Agricultural Antibiotics: Regulatory Trends
  - Table 13 U.S.-Approved Agricultural Antimicrobials
  - Table 14 Agricultural Antibiotics That Can Cross-Select Antibiotics Used to Treat Humans
  - Table 15 Common Antibiotics in Use in Livestock and Humans
- Regulatory Actions against Large-Scale Use of Avoparcin
  - Table 16 Regulatory Actions Taken by Governments to Control Agricultural Use of Avoparcin
- Prevalence of Fluoroquinolone Resistance Due to Agricultural Usage
  - Table 17 Fluoroquinolones Used in Agriculture
  - Table 18 U.S. Regulatory Actions Controlling Agricultural Use of Fluoroquinolones
- International Efforts to Address Microbial Resistance
- Action on Antibiotic Resistance (React)
- Alliance for The Prudent Use of Antibiotics (Apua)
- Efforts by The World Health Organization (Who)
  - Table 19 Antibiotics of Critical Importance to Human Medicines Categorization by The World Health Organization
- Regulatory Trends in U.S.
  - Table 20 U.S. Regulatory Bodies and Other Agencies Involved in Monitoring Agricultural Antibiotics
- Role of The Fda
- Impact of Regulations on Innovation
- Efforts by European Regulatory Agencies
- European Centre for Disease Prevention and Control (Ecdc)
- European Food Safety Authority (Efsa)
  - Table 21 E.U. Key Initiatives toward Containing Antibiotic Resistance
  - Table 22 Projects under Dg-Sanco Addressing Antibiotic Resistance
  - Table 22 (Continued)
- Regulatory Trends in Asia
- Australia
- China
- India
- Japan
- South Korea
- Taiwan
- Taiwan (Continued)
Chapter-5: Products
- Products Targeted at Antibiotic Resistance
  - Table 23 Key Products Targeting Antibiotic Resistance
- Levaquin
- Zosyn/Tazocin
- Avelox
- Cubicin
- Antibacterial Drugs in Development by Class of Product
- Beta Lactam Antibiotics
  - Table 24 B-Lactam Antibiotics, in Development or Newly Introduced
- Doripenem
- Tomopenem
- Pz-601
- Faropenem
- Ceftaroline
- Ceftobiprole
- Bal-30072
- Fr-264205
  - Table 25 B-Lactam Antibiotics, in Development or Recently Marketed
  - Table 25 (Continued)
- Fluoroquinolones
  - Table 26 Fluoroquinolone Antibiotics, in Development or Newly Introduced
- Sitafloxacin
- Garenoxacin
- Delafloxacin
- Wck-771
- Zabofloxacin
- Dc-159a
- Glycopeptides
  - Table 27 Glycopeptide Antibiotics, in Development or Newly Introduced
- Dalbavancin
- Oritavancin
- Telavancin
- Ramoplanin
- Macrolides
  - Table 28 Macrolide Antibiotics, in Development or Newly Introduced
- Cethromycin
- Edp-420
- Fidaxomicin
- Oxazolidinones
  - Table 29 Oxazolidinone Antibiotics, in Development or Newly Introduced
- Radezolid
- Torezolid
- Other Classes of Antibiotics in Pipeline
  - Table 30 Emerging Classes of Antibiotics
  - Table 31 Other Classes of Antibiotics, in Development or Newly Introduced
  - Table 31 (Continued)
  - Table 31 (Continued)
- Iclaprim
- Ptk 0796
- Afn-1252
- Friulimicin
- Rifalazil
- Pagibaximab
- Nemonoxacin
- Platensimycin
- Nxl-103
- Bc-3205 and Bc-3781
- Pmx-30063
- Kbpa-101
- Kb-001
- Achn-490
- Cb-182804
- Vaccines
  - Table 32 Vaccines against Bacterial Infections in Development or Newly Introduced
- Menveo
- Prevnar 13vpnc
- Synflorix
- V710
- Ic43
Chapter-6: Technology Trends and Patent Analysis
- Declining Trends of Innovation in The Development of New Antibiotics
  - Table 33 U.S. Fda-Approved Systemic Antibacterial Nmes, 1983 - 2008
- Broad-Spectrum Versus Narrow-Spectrum Antibiotics
  - Table 34 Systemic Antibiotics Targeting Mrsa in Clinical Development
  - Table 34 (Continued)
  - Table 35 Antibacterials against Mdr-Gram-Negative Bacteria in Clinical Development
  - Table 35 (Continued)
- New Focus on Gram-Negative Pathogens
- Analogues of Existing Antibiotics vs Novel Molecules/ Targets
  - Table 36 Analogues of Existing Drugs and New Molecules
- Cationic Peptides as New Generation Antibacterials for Therapeutic Use
  - Table 37 Comparison of Cationic Peptide Antibiotics and Conventional Antibiotics
  - Table 38 Cationic Antibacterial Peptides for Systemic Administration, under Development
- Bacterial Interference: A New Approach for The Treatment of Bacterial Infections
- Bacteriophage Therapy
- Patent Analysis
  - Table 39 U.S. Pto-Granted Patents by Antibiotic Structural Classes, 1976 - September 8, 2009
  - Table 40 Trends in Patenting of Big Pharma Companies Related to Antibiotics*
  - Table 41 Patents in Antibiotics by New and Emerging Companies, 1976 - September 8, 2009
  - Table 41 (Continued)
Chapter-7: Industry Structure
- Revival of Antibiotic Sector
- Rising Presence of Biotech Companies
  - Table 42 Selected Biotech Antibacterials in Development
  - Table 42 (Continued)
- Revival of The Sector with Renewed Interest of Big Pharma
  - Table 43 Recent Investments or Partnerships by Big Pharma Companies Targeting The Antibiotics Sector
  - Table 43 (Continued)
- Global Market for Antibiotics and Forecasts
  - Table 44 Global Growth Trends for Carbapenem Antibiotics, through 2014 ($ Millions)
  - Figure 1 Global Growth Trends for Carbapenem Antibiotics, 2008-2014 ($ Millions)
  - Table 45 Global Growth Trends for Cephalosporin Antibiotics, through 2014 ($ Millions)
  - Figure 2 Global Growth Trends for Cephalosporin Antibiotics, 2008-2014 ($ Millions)
  - Table 46 Global Growth Trends of Macrolid Antibiotics, through 2014 ($ Millions)
  - Figure 3 Global Growth Trends of Macrolid Antibiotics, 2008-2014 ($ Millions)
  - Table 47 Global Market for Beta-Lactam Antibiotics, through 2014 ($ Millions)
  - Figure 4 Global Market for Beta-Lactam Antibiotics, 2008-2014 ($ Millions)
  - Table 48 Global Market for Fluoroquinolones, through 2014 ($ Millions)
  - Figure 5 Global Market for Fluoroquinolones, 2008-2014 ($ Millions)
  - Table 49 Global Market for Bacterial Vaccines, through 2014 ($ Millions)
  - Figure 6 Global Market for Bacterial Vaccines, 2008-2014 ($ Millions)
  - Table 50 Global Antibiotic Markets, through 2014 ($ Millions)
  - Figure 7 Global Antibiotic Markets, 2008-2014 ($ Millions)
- Leading Companies in The Antibiotics Market
  - Table 51 Top Players and Key Products in The Antibiotics Market
  - Table 51 (Continued)
- Company Profiles
- Achaogen, Inc.
- Advanced Life Sciences
- Affinium Pharmaceuticals
- Arpida, Ltd.
- Basilea Pharmaceutica Ltd.
- Bayer Schering Plough Ag
- Biosynexus Inc.
- Cubist Pharmaceuticals, Inc.
- Enanta Pharmaceuticals
- Glaxo Smithkline Plc
  - Table 52 Gsk' S Pipeline Antibiotics and Bacterial Vaccine Products
  - Table 52 (Continued)
- Intercell Ag
  - Table 53 Intercell Ag' S Anti-Bacterial Pipeline Products
- Kalobios Pharmaceuticals, Inc.
- Kenta Biotech Ltd.
- Johnson &johnson
- Merck & Co. Inc.
- Mpex Pharmaceuticals
- Nabriva Therapeutics Ag
- Novabay Pharmaceuticals, Inc.
- Novartis International Ag
  - Table 54 Novartis' Bacterial Vaccine Pipeline
- Novexel
- Optimer Pharmaceuticals, Inc.
- Oscient Pharmaceuticals Corporation
- Paratek Pharmaceuticals, Inc.
- Pfizer, Inc.
- Polymedix, Inc.
- Replidyne, Inc.
- Rib-X Pharmaceuticals, Inc.
- Sanofi-Aventis
  - Table 55 Sanofi-Aventis' S Bacterial Vaccine Candidates
- Taigen Biotechnology Co., Ltd.
- Theravance, Inc.
- Trius Therapeutics
- Wyeth Pharmaceuticals
  - Table 56 Wyeth' S Antibacterial Pipeline
Appendix
- Table 57 Abbreviations
- Table 57 (Continued)
- Table 57 (Continued)

Pharmaceutical Market Research

Antibiotic Resistance and Antibiotic Technologies: Global Markets